Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

(2016) Sven Kohler et al.   CLINICAL THERAPEUTICS

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

(2016) François Briand et al.   DIABETES

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

(2016) A.J. Scheen   DIABETES & METABOLISM

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

(2016) Sunder Mudaliar et al.   DIABETES CARE

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

(2016) Muhammad Abdul-Ghani et al.   DIABETES CARE

Diabetes in Asia and the Pacific: Implications for the Global Epidemic

(2016) Arun Nanditha et al.   DIABETES CARE

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY

(2016) Alan J. Garber et al.   Endocrine Practice

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus

(2016) Curt J. Carlson et al.   Expert Opinion On Drug Safety

Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors

(2016) T. D. Filippatos et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction

(2016) Kenneth B. Margulies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

(2016)   LANCET

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

(2016) Walter N. Kernan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

(2015) Takashi Kadowaki et al.   ADVANCES IN THERAPY

Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species

(2015) Mitchell E. Taub et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers

(2015) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects

(2015) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

(2015) Christopher S. Kovacs et al.   CLINICAL THERAPEUTICS

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

(2015) Silvio E Inzucchi et al.   Diabetes & Vascular Disease Research

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

(2015) Anne L. Peters et al.   DIABETES CARE

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

(2015) Julio Rosenstock et al.   DIABETES CARE

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes

(2015) Maka S Hedrington et al.   Expert Opinion on Drug Metabolism & Toxicology

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

(2015) André J Scheen   Expert Opinion On Drug Safety

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus

(2015) Nasser Mikhail   EXPERT OPINION ON INVESTIGATIONAL DRUGS

An overview of new GLP-1 receptor agonists for type 2 diabetes

(2015) Brian Tomlinson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sotagliflozin as a potential treatment for type 2 diabetes mellitus

(2015) Bertrand Cariou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Diabetes

(2015) David M. Nathan   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

(2015) Wataru Ogawa et al.   Journal of Diabetes Investigation

Possible adverse effects of SGLT2 inhibitors on bone

(2015) Simeon I Taylor et al.   Lancet Diabetes & Endocrinology

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

(2015) Bruce A. Perkins et al.   PLoS One

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

(2014) Takashi Kadowaki et al.   ADVANCES IN THERAPY

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

(2014) Benjamin M. Scirica et al.   CIRCULATION

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus

(2014) Akiko Sarashina et al.   CLINICAL THERAPEUTICS

Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers

(2014) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

(2014) A. Liakos et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

(2014) Elizabeth M Lamos et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Luseogliflozin for the treatment of type 2 diabetes

(2014) Yutaka Seino   EXPERT OPINION ON PHARMACOTHERAPY

Empagliflozin for the treatment of type 2 diabetes

(2014) Vidhya Jahagirdar et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers

(2014) Sreeraj Macha et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers

(2013) Christian Friedrich et al.   CLINICAL THERAPEUTICS

Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

(2013) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES CARE

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

(2013) S. Macha et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

(2013) S. Macha et al.   DIABETES OBESITY & METABOLISM

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus

(2013) William N Washburn et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers

(2013) Sreeraj Macha et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

(2013) Matthew M. Riggs et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?

(2013) Anke Tönjes et al.   PHARMACOGENOMICS

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

(2013) Tim Heise et al.   Diabetes Therapy

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

(2012) Tobias Brand et al.   ADVANCES IN THERAPY

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

(2012) S. Macha et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

(2012) Akiko Sarashina et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

(2012) Sreeraj Macha et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

Intensive glucose control and macrovascular outcomes in type 2 diabetes

(2009) F. M. Turnbull et al.   DIABETOLOGIA

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association

(2008) J. S. Skyler et al.   DIABETES CARE